NCT06783166CompletedPhase 2/3
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 14 Jan 2025
- Start date
- 15 Aug 2024
- Primary completion date
- 4 Jul 2025
- Lead sponsor
- Mansoura University
- Diseases
- Heart failure
- NCT number
- NCT06783166
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 108
- From 15 Aug 2024 to the primary completion date, 4 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with any proximal tubular diuretics.
- Acute coronary syndrome within 30 days prior to randomization.
- Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.
Other illness
- Type 1 diabetes mellitus.
- Dyspnea is primarily due to non-cardiac causes.
Lab values
- An estimated glomerular filtration rate (GFR) of less than 25 ml per 1.73 m2 of body-surface area.
- Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH\>7.30 and glucose \>15 mmol/L and HCO3\>18 mmol/L).
Other
- Unable to follow instructions.
- Systolic blood pressure of less than 90 mm Hg.
- Cardiogenic shock.
- Pregnant or nursing (lactating) women.
Who the study is looking for
- Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:
- 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound. OR
- If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.
- Randomized within 24 hours of hospitalization for AHF.
- Planned use of IV loop diuretic therapy during current hospitalization
- Estimated glomerular filtration rate (eGFR) of at least 25 ml/min/1.73m2 by the MDRD equation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Noha Mansour Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
Related publications
- Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE-AHF).Clin Pharmacol Ther · 2026 · PMID 42977703
This page is information, not medical advice. Discuss any trial with your doctor.